Spotlight On

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Harry Paul Erba, MD, PhD Guest: Uma Borate, MD, MS With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it's become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.

Guest: Ilene Galinsky BSN,MSN,ANP-C Here to review the ramp-up and dosing for venetoclax therapy in patients with newly diagnosed acute myeloid leukemia is Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute.

Guest: Harry Paul Erba, MD, PhD For several decades, therapy for acute myeloid leukemia (AML) was rather straightforward. But now that we have a deeper understanding of the pathogenesis of AML, this has led to the identification of potential therapeutic targets that give us options in addition to standard intensive chemotherapy, as Dr. Harry Erba explains. BCL2-US-00026-MCVersion 2.0, Approved November 2020

Guest: Harry Paul Erba, MD, PhD Although survival among younger patients with acute myeloid leukemia (AML) has improved over the past decade, older patients continue to have a poor prognosis. And since age and frailty are the primary predictors of outcome among patients with AML, Dr. Harry Erba shares how the treatment of older patients with AML may be changing. BCL2-US-00027-MCVersion 2.0, Approved November 2020

Guest: Harry Paul Erba, MD, PhD For several decades, therapy for acute myeloid leukemia (AML) was rather straightforward. But now that we have a deeper understanding of the pathogenesis of AML, this has led to the identification of potential therapeutic targets that give us options in addition to standard intensive chemotherapy, as Dr. Harry Erba explains. BCL2-US-00026-MCVersion 2.0, Approved November 2020

Guest: Harry Paul Erba, MD, PhD Although survival among younger patients with acute myeloid leukemia (AML) has improved over the past decade, older patients continue to have a poor prognosis. And since age and frailty are the primary predictors of outcome among patients with AML, Dr. Harry Erba shares how the treatment of older patients with AML may be changing. BCL2-US-00027-MCVersion 2.0, Approved November 2020

Guest: Matthew S. Davids, MD, MMSc In addition to complete response, some clinical trials are also using minimal residual disease (MRD) to measure depth of response in chronic lymphocytic leukemia. But how exactly is MRD being defined and discussed in CLL? Here to answer that question and more is Dr. Matthew Davids, Associate Professor of Medicine at Harvard Medical School and Associate Director of the Center for Chronic Lymphocytic Leukemia at Dana-Farber Cancer Institute in Boston, Massachusetts. ABBV-US-00196-MCVersion 1.0, Approved August 2020

Guest: Matthew S. Davids, MD, MMSc In addition to complete response, some clinical trials are also using minimal residual disease (MRD) to measure depth of response in chronic lymphocytic leukemia. But how exactly is MRD being defined and discussed in CLL? Here to answer that question and more is Dr. Matthew Davids, Associate Professor of Medicine at Harvard Medical School and Associate Director of the Center for Chronic Lymphocytic Leukemia at Dana-Farber Cancer Institute in Boston, Massachusetts. ABBV-US-00196-MCVersion 1.0, Approved August 2020

Guest: MeiLan K. Han, MD, MS For patients with COPD, exacerbations can have an irreversible and sustained impact on their daily life.3,4 Additionally, exacerbations are often underreported.5 That’s why Dr. MeiLan Han is here to walk us through the importance of exacerbation recognition and prevention, the health and life burdens of exacerbations, and patient-physician communication gaps. References: Halpin DMG, Decramer M, Celli BR, et al. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017;128:85-91. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091-1097. O’Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med. 1997;155(1):109-115. Roche N. Activity limitation: a major consequence of dyspnoea in COPD. Eur Respir Rev. 2009;18(112):54-57. Leidy NK, Murray LT, Jones P, Sethi S. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(3):316-325. ©2020 AstraZeneca. All rights reserved. US-42455 Last Updated 8/20

Guest: MeiLan K. Han, MD, MS For patients with COPD, exacerbations can have an irreversible and sustained impact on their daily life.3,4 Additionally, exacerbations are often underreported.5 That’s why Dr. MeiLan Han is here to walk us through the importance of exacerbation recognition and prevention, the health and life burdens of exacerbations, and patient-physician communication gaps. References: Halpin DMG, Decramer M, Celli BR, et al. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017;128:85-91. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091-1097. O’Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med. 1997;155(1):109-115. Roche N. Activity limitation: a major consequence of dyspnoea in COPD. Eur Respir Rev. 2009;18(112):54-57. Leidy NK, Murray LT, Jones P, Sethi S. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(3):316-325. ©2020 AstraZeneca. All rights reserved. US-42455 Last Updated 8/20

Host: Matt Birnholz, MD Guest: Roger Kornu, MD To help address the gap in awareness across the field regarding the development of psoriatic arthritis, Dr. Roger Kornu joins Dr. Matt Birnholz at the 2019 American College of Rheumatology annual meeting in Atlanta, Georgia, to discuss commonly overlooked symptoms, including plaque psoriasis, dactylitis, and enthesitis. PP-IX-US-3710 04/2020 ©Lilly USA, LLC 2020. All rights reserved.

Host: Matt Birnholz, MD Guest: Sanjay Chabra, MD As stated by Dr. Sanjay Chabra, "About 19 percent of the population lives with chronic back pain, but what about when it’s inflammatory—not mechanical—back pain?" Join Dr. Matt Birnholz as he sits down with Dr. Chabra at the 2019 American College of Rheumatology annual meeting in Atlanta, Georgia, to share strategies that can help us shorten the delay in the diagnosis of ankylosing spondylitis that often occurs within and around rheumatology practices. PP-IX-US-3710 04/2020 ©Lilly USA, LLC 2020. All rights reserved.

Host: Matt Birnholz, MD Guest: Roger Kornu, MD To help address the gap in awareness across the field regarding the development of psoriatic arthritis, Dr. Roger Kornu joins Dr. Matt Birnholz at the 2019 American College of Rheumatology annual meeting in Atlanta, Georgia, to discuss commonly overlooked symptoms, including plaque psoriasis, dactylitis, and enthesitis. PP-IX-US-3710 04/2020 ©Lilly USA, LLC 2020. All rights reserved.

Host: Matt Birnholz, MD Guest: Sanjay Chabra, MD As stated by Dr. Sanjay Chabra, "About 19 percent of the population lives with chronic back pain, but what about when it’s inflammatory—not mechanical—back pain?" Join Dr. Matt Birnholz as he sits down with Dr. Chabra at the 2019 American College of Rheumatology annual meeting in Atlanta, Georgia, to share strategies that can help us shorten the delay in the diagnosis of ankylosing spondylitis that often occurs within and around rheumatology practices. PP-IX-US-3710 04/2020 ©Lilly USA, LLC 2020. All rights reserved.

Host: Matt Birnholz, MD Guest: Ara Dikranian, MD Did you know joint stiffness and tenderness as well as joint pain could be early signs and symptoms of rheumatoid arthritis? Once symptoms are identified, how do you know which patients should be referred to a rheumatologist? Answering those and other questions is Dr. Ara Dikranian, who sat down with Dr. Matt Birnholz at the annual rheumatology meeting in Atlanta, Georgia. PP-BA-US-1143 2/2020 ©Lilly USA, LLC 2020. All rights reserved.

Host: Matt Birnholz, MD Guest: Smitha Reddy, MD Join Dr. Matt Birnholz as he sits down with Dr. Smitha Reddy at the annual rheumatology meeting in Atlanta, Georgia to explore how an anti-inflammatory diet could have an impact on a rheumatoid arthritis patient's lifestyle. PP-BA-US-1149 2/2020 ©Lilly USA, LLC 2020. All rights reserved.

Host: Matt Birnholz, MD Guest: Ara Dikranian, MD Did you know joint stiffness and tenderness as well as joint pain could be early signs and symptoms of rheumatoid arthritis? Once symptoms are identified, how do you know which patients should be referred to a rheumatologist? Answering those and other questions is Dr. Ara Dikranian, who sat down with Dr. Matt Birnholz at the annual rheumatology meeting in Atlanta, Georgia. PP-BA-US-1143 2/2020 ©Lilly USA, LLC 2020. All rights reserved.

Host: Matt Birnholz, MD Guest: Smitha Reddy, MD Join Dr. Matt Birnholz as he sits down with Dr. Smitha Reddy at the annual rheumatology meeting in Atlanta, Georgia to explore how an anti-inflammatory diet could have an impact on a rheumatoid arthritis patient's lifestyle. PP-BA-US-1149 2/2020 ©Lilly USA, LLC 2020. All rights reserved.

Host: Paul Doghramji, MD Guest: David H. Peyton, Ph.D. The vaping epidemic is becoming more and more concerning, but could new research prompt people to quit? To find out, Dr. Paul Doghramji speaks with Dr. David Peyton about his recent study that challenges the claim that vaping devices take less of a toll on our health than tobacco smoking.

Host: Jennifer Caudle, DO Guest: Sergio Schwartzman, MD Since primary care physicians are on the frontlines of healthcare, they play an important role in not only diagnosing and managing patients with spondyloarthritis, but also referring those patients to rheumatologists when appropriate. Here to walk through what primary care physicians should consider is rheumatologist Dr. Sergio Schwartzman. This activity is intended for United States and Puerto Rico health care professionals only.

Host: Sergio Schwartzman, MD Guest: Michael Payette, MD, MBA, FAAD Patients with spondyloarthritis can experience a wide range of dermatologic manifestations ranging from psoriasis to erythema nodosum, making collaborative care between rheumatologists and dermatologists essential. Here to talk about how rheumatologists like Dr. Sergio Schwartzman can manage and refer patients with spondyloarthritis to dermatologists—and vice versa—is Dr. Michael Payette, co-founder of Central Connecticut Dermatology. This activity is intended for United States and Puerto Rico health care professionals only.

Host: Sergio Schwartzman, MD Guest: Stephen Hanauer, MD Even though there’s a known relationship between inflammatory bowel disease (IBD) and spondyloarthritis, not all arthropathies associated with IBD signal spondyloarthritis. So how can gastroenterologists and rheumatologists work together to identify and manage those that are? That’s what rheumatologist Dr. Sergio Schwartzman breaks down with Dr. Stephen Hanauer, Medical Director of the Digestive Health Center at Northwestern University Feinberg School of Medicine. This activity is intended for United States and Puerto Rico health care professionals only.

Host: Jennifer Caudle, DO Guest: Sergio Schwartzman, MD Since primary care physicians are on the frontlines of healthcare, they play an important role in not only diagnosing and managing patients with spondyloarthritis, but also referring those patients to rheumatologists when appropriate. Here to walk through what primary care physicians should consider is rheumatologist Dr. Sergio Schwartzman. This activity is intended for United States and Puerto Rico health care professionals only.

Host: Sergio Schwartzman, MD Guest: Michael Payette, MD, MBA, FAAD Patients with spondyloarthritis can experience a wide range of dermatologic manifestations ranging from psoriasis to erythema nodosum, making collaborative care between rheumatologists and dermatologists essential. Here to talk about how rheumatologists like Dr. Sergio Schwartzman can manage and refer patients with spondyloarthritis to dermatologists—and vice versa—is Dr. Michael Payette, co-founder of Central Connecticut Dermatology. This activity is intended for United States and Puerto Rico health care professionals only.

Host: Sergio Schwartzman, MD Guest: Stephen Hanauer, MD Even though there’s a known relationship between inflammatory bowel disease (IBD) and spondyloarthritis, not all arthropathies associated with IBD signal spondyloarthritis. So how can gastroenterologists and rheumatologists work together to identify and manage those that are? That’s what rheumatologist Dr. Sergio Schwartzman breaks down with Dr. Stephen Hanauer, Medical Director of the Digestive Health Center at Northwestern University Feinberg School of Medicine. This activity is intended for United States and Puerto Rico health care professionals only.

Host: Sergio Schwartzman, MD Guest: Jennifer Thorne, MD, PhD Did you know that more than 20 percent of patients with spondyloarthritis experience at least one episode of uveitis? Or that nearly half of patients with uveitis may also have undiagnosed spondyloarthritis? That’s why co-managed care is so important for these patients, as rheumatologist Dr. Sergio Schwartzman and ophthalmologist Dr. Jennifer Thorne explain. This activity is intended for United States and Puerto Rico health care professionals only.

Host: Sergio Schwartzman, MD Guest: Jennifer Thorne, MD, PhD Did you know that more than 20 percent of patients with spondyloarthritis experience at least one episode of uveitis? Or that nearly half of patients with uveitis may also have undiagnosed spondyloarthritis? That’s why co-managed care is so important for these patients, as rheumatologist Dr. Sergio Schwartzman and ophthalmologist Dr. Jennifer Thorne explain. This activity is intended for United States and Puerto Rico health care professionals only.

Host: Andrea J. Singer, MD, FACP, CCD Guest: Michael Lewiecki, MD, FACP, FACE Even though two million Americans suffer from hip fractures every year, the good news is that this number could be cut in half if the appropriate, preventative measures are implemented. Joining Dr. Andrea Singer to discuss those interventions is Dr. Michael Lewiecki, Vice President of the Board of Trustees of the National Osteoporosis Foundation.

Host: Matt Birnholz, MD Guest: Susan Greenspan, MD Guest: John Carey, MB, BCh, BAO It is estimated that 54 million Americans over the age of 50 are affected by osteoporosis and low-density bone mass, putting them at higher risk for fractures. Additionally, new evidence is emerging that the 30-year downward trend in hip fractures has hit a plateau recently, indicating that the field, as a whole, must take action to aggressively reduce this danger in our aging population. Dr. John Carey, President of the International Society for Clinical Densitometry, and Dr. Susan Greenspan, Vice President of the National Osteoporosis Foundation, speak with host Dr. Matt Birnholz about diagnostic and treatment priorities for osteoporosis to help reduce fractures.

Host: Matt Birnholz, MD Guest: Susan Greenspan, MD Guest: John Carey, MB, BCh, BAO It is estimated that 54 million Americans over the age of 50 are affected by osteoporosis and low-density bone mass, putting them at higher risk for fractures. Additionally, new evidence is emerging that the 30-year downward trend in hip fractures has hit a plateau recently, indicating that the field, as a whole, must take action to aggressively reduce this danger in our aging population. Dr. John Carey, President of the International Society for Clinical Densitometry, and Dr. Susan Greenspan, Vice President of the National Osteoporosis Foundation, speak with host Dr. Matt Birnholz about diagnostic and treatment priorities for osteoporosis to help reduce fractures.

Dr. Becky Fitzgerald, a dermatologist in private practice in Los Angeles, CA and on the clinical faculty at UCLA, and Dr. Sabrina Fabi, dermatologist, assistant clinical professor at the University of California, San Diego, and associate at Cosmetic Laser Dermatology, discuss Poly-L-lactid Acid (PLLA) injections and how to best employ this unique product cosmetically for patients.

Dr. Becky Fitzgerald, a dermatologist in private practice in Los Angeles, CA and on the clinical faculty at UCLA, and Dr. Sabrina Fabi, dermatologist, assistant clinical professor at the University of California, San Diego, and associate at Cosmetic Laser Dermatology, discuss Poly-L-lactid Acid (PLLA) injections and how to best employ this unique product cosmetically for patients.

Drug diversion is the illegal distribution or abuse of prescription drugs or their use for unintended purposes. The diversion of prescription drugs may occur at any point as prescription drugs are distributed from the manufacturer to wholesale distributors, to pharmacies, and ultimately to the patient. Though this problem is nearly universal among healthcare instititions, many don't have adequate processes in place to detect it. Moreover, concerns about civil and regulatory liability, as well as negative publicity, often impede healthcare organizations from reporting instances of drug diversion. Dr. Howard Zucker, New York State Department of Health Commissioner, speaks with noted provider drug diversion expert Kimberly New, JD, BSN, RN about how prevalent the problem of drug diversion is, the signs of potential drug diversion activity, and how to set up a robust facility program to avert potential diversion events. This program is provided on behalf of the New York One and Only Campaign, a public health effort led by the Centers for Disease Control and Prevention (CDC) and the Safe Injection Practices Coalition (SIPC) to raise awareness among patients and healthcare providers about safe injection practices.

Drug diversion is the illegal distribution or abuse of prescription drugs or their use for unintended purposes. The diversion of prescription drugs may occur at any point as prescription drugs are distributed from the manufacturer to wholesale distributors, to pharmacies, and ultimately to the patient. Though this problem is nearly universal among healthcare instititions, many don't have adequate processes in place to detect it. Moreover, concerns about civil and regulatory liability, as well as negative publicity, often impede healthcare organizations from reporting instances of drug diversion. Dr. Howard Zucker, New York State Department of Health Commissioner, speaks with noted provider drug diversion expert Kimberly New, JD, BSN, RN about how prevalent the problem of drug diversion is, the signs of potential drug diversion activity, and how to set up a robust facility program to avert potential diversion events. This program is provided on behalf of the New York One and Only Campaign, a public health effort led by the Centers for Disease Control and Prevention (CDC) and the Safe Injection Practices Coalition (SIPC) to raise awareness among patients and healthcare providers about safe injection practices.

Host: Jennifer Caudle, DO Guest: Michael Lewiecki, MD, FACP, FACE With an incidence rate of more than 750,000 per year, vertebral fractures contribute significantly to morbidity and mortality rates in osteoporosis patients, particularly those who have sustained a VCF in the past. In this new segment, we will hear from Dr. Michael Lewiecki, as he examines this debilitating issue. Dr. Lewiecki is the Director of the New Mexico Clinical Research and Osteoporosis Center; and, Clinical Assistant Professor of Medicine at UNM School of Medicine in Albuquerque, New Mexico.

Host: Jennifer Caudle, DO Guest: Michael Lewiecki, MD, FACP, FACE With an incidence rate of more than 750,000 per year, vertebral fractures contribute significantly to morbidity and mortality rates in osteoporosis patients, particularly those who have sustained a VCF in the past. In this new segment, we will hear from Dr. Michael Lewiecki, as he examines this debilitating issue. Dr. Lewiecki is the Director of the New Mexico Clinical Research and Osteoporosis Center; and, Clinical Assistant Professor of Medicine at UNM School of Medicine in Albuquerque, New Mexico.

Host: Shira Johnson, MD Guest: Meryl S. LeBoff, MD Osteoporosis is a major public health threat for an estimated 54 million Americans 50 years of age and older. In the U.S. today, 10.2 million individuals are estimated to already have the disease and 43.4 million more are estimated to have low bone mass, placing them at increased risk for osteoporosis and fractures. Because bone density tends to decline with age, the problem of osteoporosis has reached epidemic proportions with the rapidly aging population. It is estimated that by 2020 over 61 million Americans will have osteoporosis or low bone mass. Join host Dr. Shira Johnson welcomes Dr. Meryl LeBoff, Endocrinologist; Chief of the Calcium and Bone Section at Brigham Women's Hospital in Boston, Massachusetts; and, trustee of the National Osteoporosis Foundation. About NOF & Fracture Liaison Service (FLS) NOF has adopted the 20/20 Vision of the National Bone Health Alliance (NBHA), of which NOF is a founding member. The goal is to reduce bone breaks by 20% by the year 2020. Approximately 2 million fractures are caused by osteoporosis each year. Compliance around osteoporosis and post-fracture quality measures is not consistent despite the existence of several NCQA and CMS healthcare provider quality measures. The solution to resolving the 75 ...

Host: Shira Johnson, MD Guest: Meryl S. LeBoff, MD Osteoporosis is a major public health threat for an estimated 54 million Americans 50 years of age and older. In the U.S. today, 10.2 million individuals are estimated to already have the disease and 43.4 million more are estimated to have low bone mass, placing them at increased risk for osteoporosis and fractures. Because bone density tends to decline with age, the problem of osteoporosis has reached epidemic proportions with the rapidly aging population. It is estimated that by 2020 over 61 million Americans will have osteoporosis or low bone mass. Join host Dr. Shira Johnson welcomes Dr. Meryl LeBoff, Endocrinologist; Chief of the Calcium and Bone Section at Brigham Women's Hospital in Boston, Massachusetts; and, trustee of the National Osteoporosis Foundation. About NOF & Fracture Liaison Service (FLS) NOF has adopted the 20/20 Vision of the National Bone Health Alliance (NBHA), of which NOF is a founding member. The goal is to reduce bone breaks by 20% by the year 2020. Approximately 2 million fractures are caused by osteoporosis each year. Compliance around osteoporosis and post-fracture quality measures is not consistent despite the existence of several NCQA and CMS healthcare provider quality measures. The solution to resolving the 75 ...